The manufacture of the required cannabis wafers for clinical trials is set to commence in the coming weeks, with phase I clinical trials to commence shortly thereafter.
Bod chief executive officer Jo Patterson said: “Having finalised the formulation of Medicabilis in WaferiX form we have another major milestone for the company as it tracks towards the commencement of its phase I clinical trial program.”
The sublingual cannabis wafer is a unique combination of Bod’s proprietary ECs315 cannabis extract and iX Biopharma’s ‘WaferiX’ technology.
The formulated product, containing Bod’s proprietary cannabis extract, which has been freeze dried into a sublingual wafer, can be placed under the patient’s tongue.
The wafer dissolves rapidly